





# Results of the 3<sup>rd</sup> Quarter 2019



Jan A. Alfheim  
CEO

# Agenda

1. Welcome to the 3<sup>rd</sup> Quarter 2019 presentation
2. Highlights from the 3<sup>rd</sup> Quarter
3. Status Radspherin<sup>®</sup> development
4. Financials
5. Q&A



# Highlights from the 3<sup>rd</sup> Quarter



# Radspherin<sup>®</sup> patent issues in Japan

- This patent protection of Radspherin<sup>®</sup> will remain in effect until July 2036.
- The company now has patent protection for Radspherin<sup>®</sup> in the all major pharmaceutical markets including Japan, USA, and Europe.



## Oncoinvent's 1<sup>st</sup> Industrial PhD graduate!

- Sara Westrøm defended her PhD thesis on the 5<sup>th</sup> of September at the Radium Hospital.
- Her work has resulted in four research publications relating to Radspherin<sup>®</sup>.
- Sara is co-inventor on Oncoinvent's Radspherin<sup>®</sup> patent.



Dr. Sara Westrøm, Ph.D. has joined the Oncoinvent R&D team as Senior Research Scientist



# Status Radspherin® development



# Radspherin<sup>®</sup>

alpha-emitting microparticles for local applications

## **SPECIALLY DESIGNED $\text{CaCO}_3$ microparticles**

- Carriers for the alpha-emitting isotope
- Degradable and non-toxic
- Good regional retention, low systemic exposure

## **A NEW alpha-emitting radioisotope Ra-224**

- High energetic radiation for efficient tumor cell kill
- Local deposition of radiation
- Therapeutic relevant temporal and spatial window
- Low probability of unintended radiation damage





## Moving to the next stage of development

- The company is concentrating efforts to generate the necessary documents to send in new clinical trial applications (CTA's) in Q4
- Applications actually need to be sent to 3 separate authorities in each country in order to start the clinical trials

# Regulatory Submissions for Phase 1

Study	Country	Submissions to ethics committees (LEC/CEC)	Submissions to regulatory authorities	Submissions to Radiation Safety Authorities
RAD-18-001 Ovarian Cancer	Norway	Initial submission approved Amendment to be submitted to CEC	To be submitted: Re-submission to NoMA	Approved by DSA
	Belgium	To be submitted to CEC	To be submitted to FAHMP	Application for FANC licenses submitted (Site, import, clinical study) To be submitted: response to questions
	Germany	To be submitted to LEC and CEC	Oct 2019: Submitted to BfArM	To be submitted to BfS after CEC approval
RAD-18-002 Colorectal Cancer	Norway	Initial submission approved Amendment to be submitted to CEC	To be submitted: Re-submission to NoMA	Approved by DSA
	Sweden	To be submitted to CEC (Biobank application after CEC approval)	To be submitted to MPA	NA



# Presentations



# European Association of Nuclear Medicine (EANM) 2019 in Barcelona



CSO Tina B. Bønsdorff presented the  
*"Feasibility of Ra-224 SPECT/CT imaging in a therapeutic setting - a phantom study"*  
on behalf of Oncoinvent and the Norwegian Radiumhospital during the European Association of Nuclear Medicine (EANM) 2019 in Barcelona



Tina Bønsdorff, CSO



# Financials




# Q3-2019 Financial figures

High activity within R&D combined with strict expense discipline

KEY FIGURES AMOUNTS IN NOK	3rd QUARTER		YTD		FULL YEAR
	2019	2018	2019	2018	2018
<b>TOTAL REVENUES AND OTHER INCOME</b>	<b>1 617 603</b>	<b>2 369 061</b>	<b>3 187 333</b>	<b>4 122 633</b>	<b>10 458 850</b>
Payroll and related expenses	5 994 221	2 637 726	16 691 176	10 276 717	15 617 140
Other operating expenses	4 367 638	4 410 389	16 133 211	17 806 543	25 592 754
<b>TOTAL OPERATING EXPENSES</b>	<b>10 361 859</b>	<b>7 048 115</b>	<b>32 824 387</b>	<b>28 083 261</b>	<b>41 209 894</b>
<b>EBITDA</b>	<b>- 8 744 256</b>	<b>- 4 679 054</b>	<b>- 29 637 054</b>	<b>- 23 960 628</b>	<b>- 30 751 044</b>
Depreciation and amortization	1 091 642	1 008 741	3 269 164	2 887 731	3 987 007
<b>EBIT</b>	<b>- 9 835 898</b>	<b>- 5 687 795</b>	<b>- 32 906 218</b>	<b>- 26 848 359</b>	<b>- 34 738 051</b>
Finance cost and other income	52 327	5 969	68 536	21 720	1 686 127
<b>NET PROFIT(LOSS) FOR THE PERIOD</b>	<b>- 9 888 225</b>	<b>- 4 673 085</b>	<b>- 32 974 754</b>	<b>- 26 826 639</b>	<b>- 33 051 924</b>
Net Proceeds from equity issue	-	25 000	125 000	25 000	25 000
Cash and cash equivalents, end of period	125 562 444	159 571 983	125 562 444	159 571 983	153 553 317
Total number of shares, beginning of period	13 190 411	13 187 181	13 187 181	13 184 681	13 184 681
Total number of shares, end of period	13 190 411	13 187 181	13 190 411	13 187 181	13 187 181

- Operating expenses of NOK 10.4 mill for the quarter and NOK 32.8 mill. YTD
- Cash position of NOK 125.6 mill. estimated to be sufficient to complete dose range escalation phase of phase 1 clinical trials

## Distribution of operating expenses incl. depreciation YTD Q3-2019



- Dynamic organization with employees that are multidisciplined and able to contribute cross multiple departments
- At current stage; large fluctuation of resources between department
- G&A include infrastructure expenses such as lease, IT services, patents etc.



Q & A





